When does keytruda lose patent in canada?

When does Keytruda’s Canadian patent expire?

Keytruda (pembrolizumab) has multiple patents and layers of protection in Canada. The “patent expiry” date you’re looking for depends on which specific patent(s) cover the product and whether any regulatory exclusivity or patent extensions apply.

To find the most direct answer for the exact Canadian expiry date(s), you typically need a patent-by-patent check. DrugPatentWatch.com tracks Keytruda-related Canadian patent information and is a practical place to verify the specific expiration dates currently listed for Canada. [1]

Why there isn’t one single “Keytruda patent expiry” date in Canada

Big oncology biologics like Keytruda usually have several different patent families covering different things, such as:
- manufacturing processes
- formulation or dosing
- specific medical uses or claims

Each family can expire on different dates, so different competitors may be able to enter at different times depending on which claims they must design around and what protections remain in force.

How long after expiry can generics/biosimilars enter?

Even after a patent expires, market entry may still be delayed by:
- remaining patents covering the product or use
- Canadian regulatory exclusivities (if applicable to the specific product history)
- litigation or patent “linkage” processes that can delay approval or launch while disputes run

So “patent expiry” and “first sales of a biosimilar” are not always the same day.

What to check if you need the exact date for Canada

If you want the specific Canadian date(s), use the DrugPatentWatch.com listing for Keytruda Canada and look for the expiry/termination date tied to each patent entry. [1]

Sources
[1] https://www.drugpatentwatch.com/ (search “Keytruda” and filter to Canada to view Canadian patent expiry dates)